HEXOPRENALINE

Details

Stereochemistry	MIXED
Molecular Formula	C22H32N2O6
Molecular Weight	420.4993
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(CNCCCCCCNCC(O)C1=CC(O)=C(O)C=C1)C2=CC=C(O)C(O)=C2

InChI

InChIKey=OXLZNBCNGJWPRV-UHFFFAOYSA-N

InChI=1S/C22H32N2O6/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16/h5-8,11-12,21-30H,1-4,9-10,13-14H2

HIDE SMILES / InChI

Molecular Formula	C22H32N2O6
Molecular Weight	420.4993
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789
Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html

Hexoprenaline is a selective beta2-adrenoreceptor agonist indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. In many countries the drug is used as tocolytic agent (under the trade name gynipral).

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 203 Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Asthma 241 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789	Palliative	Approved 8429	Unknown Approved Use Unknown
Bronchitis 51 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789	Primary	Approved 8429	Unknown Approved Use Unknown
Emphysema 13 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789	Primary	Approved 8429	Unknown Approved Use Unknown
Premature labour 10 Sources: https://www.medicinep.com/gynipral-tocolytic-uterorelaxant-637.html	Preventing	Approved 8429	GYNIPRAL Approved Use Gynipral prevents threatened abortion with premature labour.

PubMed

Title	Date	PubMed
Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants.	2001	11687053
The effects of fetal breathing movements on the utero-fetal-placental circulation.	2001 Jan	11753512
A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation.	2004 Apr	15008765
Beta 2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats.	2004 Sep	15278905
Flow injection potentiometric assay of hexoprenaline in its pure state, pharmaceutical preparations, and biological samples.	2008	18483573
Treatment of pregnant women with a betamimetic and verapamil increases the micronuclei frequency in umbilical cord blood lymphocytes.	2008 Aug	18679011
Dependence of the lymphocyte proliferative response on the endogenous cortisol level and sensitivity to β-adrenergic regulation in vitro in the early period of penetrating eye injury.	2010 Sep-Oct	20963649

Sample Use Guides

In Vivo Use Guide

Hexoprenaline can be given by metered aerosol in doses of 200 to 400μg, up to 5 times daily (in asthma), or as an infusion of 0,30 ug and 0,45 ug per minute or as 1-2 tablets q.i.d (0.5 mg per tablet) (maintenance dose in premature labour).

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:36:15 GMT 2023` Edited by `admin` on `Fri Dec 15 18:36:15 GMT 2023`
Record UNII	G9L6B3W684
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HEXOPRENALINE

Official Name

English

ST-1512

Code

English

HEXOPRENALINE [MI]

Common Name

English

hexoprenaline [INN]

Common Name

English

ST1512

Code

English

IPRADOL

Brand Name

English

1,2-BENZENEDIOL, 4,4'-(1,6-HEXANEDIYLBIS(IMINO(1-HYDROXY-2,1-ETHANEDIYL)))BIS-

Systematic Name

English

Hexoprenaline [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

R03AC06